Showing results (81-90 of 207) with videos related to

Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2024
Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility TestingThomas P Lodise, Sujata M Bhavnani, Paul G Ambrose, et al.
The Journal of Infectious Diseases|December 28, 2006
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growthTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Diagnostic Microbiology and Infectious Disease|June 28, 2008
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumoniaSujata M Bhavnani, Alan Forrest, Jeffrey P Hammel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 23, 2007
Back to the future: using aminoglycosides again and how to dose them optimallyGeorge L Drusano, Paul G Ambrose, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Postgraduate Medical Journal|August 17, 1999
Primary antibody deficiency and Crohn's diseaseP Conlong, W Rees, J L Shaffer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymorePaul G Ambrose, Sujata M Bhavnani, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2025
Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumoniaScott A Van Wart, Michael Trang, M Courtney Safir, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2009
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremiaChristopher M Rubino, Scott A Van Wart, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2006
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremiaSujata M Bhavnani, Julie A Passarell, Joel S Owen, et al.
Pageof 21